NP-5497-KA

NP-5497-KA is a highly selective κ-opioid receptor agonist with oral activity. Preclinical research demonstrates that NP-5497-KA exhibits a 1000-fold greater selectivity for the κ-opioid receptor compared to the μ-opioid receptor, which is considerably higher than previous compounds like nalfurafine. This specificity is significant as κ-opioid agonists are being explored for pain management and opioid use disorder due to their reduced risk of classic opioid-induced side effects such as respiratory depression, constipation, abuse, and addiction. NP-5497-KA has demonstrated efficacy in animal models in modulating morphine-induced reward-related behaviors and may represent a promising option for treating opioid use disorder with a more favorable side effect profile compared to conventional opioid therapies. The compound has been primarily utilized in research settings, with evidence supporting its analgesic and anti-addictive potential[1][3][4][5][8].